Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
investors
VSTM Overaction to Black Box Label Creates Buying Opportunity
For months Verastem Oncology (VSTM) investors have been eagerly awaiting the FDA's decision on it's lead product Duvelisib; a PI3K-δ (delta) and PI3K-γ (gamma) inhibitor that was granted Orphan Drug … [Read more...] about VSTM Overaction to Black Box Label Creates Buying Opportunity
ADMP Poised For NDA Approval
On August 27th, 2018 MS Money Moves initiated coverage on Adamis Pharmaceuticals (ADMP). At the time it was trading at $2.85 per share. Our analysis of the company indicated that it was oversold and … [Read more...] about ADMP Poised For NDA Approval
Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
Today September 20th Galectin Therapeutics (NASDAQ: GALT) announced promising results from their phase 1b clinical trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial. … [Read more...] about Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
GR-MD-02: Keytrua’s Partner, Cancer’s Nemesis
Tumors excrete elevated level of galectin-3 Galectin-3 diminishes T-cells’ ability to kill tumor cells Galectin-3 aids in cancer progression GR-MD-02 is safe, effective, and … [Read more...] about GR-MD-02: Keytrua’s Partner, Cancer’s Nemesis
Swing Trading a Biotech Stock
Overview Swing Trading is a trading strategy that involves buying a stock at a lower price and selling it at a higher price over a short period of time. Return on investment targets ranges from … [Read more...] about Swing Trading a Biotech Stock
GALT is Primed for Acquisition or Partnership
Overview Galectin Therapeutics (NASDAQ GALT $5.96) is a leader in the development of a treatment for Non-Alcoholic SteatoHepatitis, an unmet medical need worth billions. Their star drug … [Read more...] about GALT is Primed for Acquisition or Partnership
You must be logged in to post a comment.